Expression Profiles of miR-22-5p and miR-142-3p Indicate Hashimoto’s Disease and Are related to Thyroid Antibodies

Abstract

Hashimoto’s thyroiditis (HT) is the most prevalent autoimmune disorder of the thyroid (AITD) and characterized by the presence of circulating autoantibodies evoked by a, to date, not fully understood dysregulation of the immune system. Autoreactive lymphocytes and inflammatory processes in the thyroid gland can impair or enhance thyroid hormone secretion. MicroRNAs (miRNAs) are small noncoding RNAs, which can play a pivotal role in immune functions and the development of autoimmunity. The aim of the present study was to evaluate whether the expression of 9 selected miRNAs related to immunological functions differ in patients with HT compared to healthy controls. MiRNA profiles were analysed using quantitative reverse transcription polymerase chain reaction (qRT-PCR) in 24 patients with HT and 17 healthy controls. Systemic expressions of miR-21-5p, miR-22-3p, miR-22-5p, miR-142-3p, miR-146a-5p, miR-301-3p and miR-451 were significantly upregulated in patients with HT (p ≤ 0.01) and were suitable to discriminate between HT and healthy controls in AUC analysis. Altered expressions of miR-22-5p and miR-142-3p were associated with higher levels of thyroid antibodies, suggesting their contribution to the pathogenesis of HT.

Serum Expression of miR-23a-3p and miR-424-5p Indicate Specific Polycystic Ovary Syndrome Phenotypes: A Pilot Study

“…The latter two miRNAs showed expressions at the detection limit in our cohort. Serum and plasma differ in their content of miRNA derived from different blood cells [ 55 , 56 , 57 ], which may explain these incongruent findings. However, there are further inconsistencies for miR-155-5p and miR-29a-5p (both show expression at the detection limit in our data) that cannot be explained by differences in demographic diversity, analytical method or sample type.…”

Study on the Potential Mechanism of miR-22-5p in Non-Small-Cell Lung Cancer

“…miR-22-5p is a member of the miR-22 family and is located on chromosome 17p13.3. It has active regulatory effects in a series of diseases, such as acute myocardial infarction, Hashimoto's disease [22][23][24], and multiple tumors, by targeting the vascular endothelial factor, intercellular adhesion molecule 1, or Rasassociation proximate 1/extracellular-signal regulated kinase signaling pathways [25][26][27]. In the present study, a series of target genes of miR-22-5p were predicted, as miR-22-5p could regulate the migration, proliferation, and EMT, the target of miR-22-5p must be associated to tumor malignant progression, and then we clarified that miR-22-5p could directly target TWIST2, a transcription factor associated with tumor malignant progression [28].…”

Association between genetic variants of microRNA‐21 and microRNA‐155 and systemic lupus erythematosus: A case‐control study from a Chinese population

“…Alteration in miR-21 expression has been observed in some autoimmune diseases. 41,42 miRNA profile and RT-qPCR were performed to estimate the abnormality expressed in circulating miRNAs in individuals with SLE compared to patients with RA and also to healthy controls. Wang H et al 43 showed that miR-21 was upregulated in the SLE patients and was also significantly increased in RA patients.…”

“…Furthermore, recent studies have reported that miRNAs in the body can be tested in circulation and become potential biomarkers in various diseases. Alteration in miR‐21 expression has been observed in some autoimmune diseases 41,42 . miRNA profile and RT‐qPCR were performed to estimate the abnormality expressed in circulating miRNAs in individuals with SLE compared to patients with RA and also to healthy controls.…”